0001493152-20-002701.txt : 20200219 0001493152-20-002701.hdr.sgml : 20200219 20200219095641 ACCESSION NUMBER: 0001493152-20-002701 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200219 DATE AS OF CHANGE: 20200219 EFFECTIVENESS DATE: 20200219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adhera Therapeutics, Inc. CENTRAL INDEX KEY: 0000737207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 112658569 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-360856 FILM NUMBER: 20627835 BUSINESS ADDRESS: STREET 1: P.O. BOX 2161 CITY: WAKE FOREST STATE: NC ZIP: 27588 BUSINESS PHONE: 919-578-5901 MAIL ADDRESS: STREET 1: P.O. BOX 2161 CITY: WAKE FOREST STATE: NC ZIP: 27588 FORMER COMPANY: FORMER CONFORMED NAME: Marina Biotech, Inc. DATE OF NAME CHANGE: 20100722 FORMER COMPANY: FORMER CONFORMED NAME: MDRNA, Inc. DATE OF NAME CHANGE: 20080610 FORMER COMPANY: FORMER CONFORMED NAME: NASTECH PHARMACEUTICAL CO INC DATE OF NAME CHANGE: 19920703 D 1 primary_doc.xml X0708 D LIVE 0000737207 Adhera Therapeutics, Inc. BOX 2161 WAKE FOREST NC NORTH CAROLINA 27588 919-518-3748 DELAWARE NASTECH PHARMACEUTICAL CO. INC. Marina Biotech, Inc. MDRNA, Inc. NASTECH PHARMACEUTICAL CO INC Corporation true Nancy Phelan c/o Adhera Therapeutics, Inc. PO BOX 2161 WAKE FOREST NC NORTH CAROLINA 27588 Executive Officer Director Uli Hacksell c/o Adhera Therapeutics, Inc. PO BOX 2161 WAKE FOREST NC NORTH CAROLINA 27588 Director Tim Boris c/o Adhera Therapeutics, Inc. PO BOX 2161 WAKE FOREST NC NORTH CAROLINA 27588 Director Rhonda Stanley c/o Adhera Therapeutics, Inc. PO BOX 2161 WAKE FOREST NC NORTH CAROLINA 27588 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2019-06-28 false true true true false 499950 Maxim Group LLC 120708 None None 405 LEXINGTON AVE. NEW YORK NY NEW YORK 10174 CT CONNECTICUT MD MARYLAND NJ NEW JERSEY false 499950 499950 0 false 1 49995 true 0 The issuer intends to pay to Maxim Group LLC a placement fee equal to 10% of the aggregate gross proceeds of the offering. 0 A portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3. false Adhera Therapeutics, Inc. /s/ Nancy R. Phelan Nancy R. Phelan Chief Executive Officer 2020-02-19